These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23677743)

  • 21. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
    Setnik B; Bramson C; Bass A; Levy-Cooperman N; Malhotra B; Matschke K; Sommerville KW; Wolfram G; Geoffroy P
    J Clin Pharmacol; 2015 Dec; 55(12):1351-61. PubMed ID: 26011742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic Bioequivalence Studies of an Extended-Release Oxycodone Hydrochloride Tablet in Healthy Japanese Subjects Under Fasting and Fed Conditions Without an Opioid Antagonist.
    Toyama K; Furuie H; Kuroda K; Ishizuka H
    Drugs R D; 2017 Sep; 17(3):363-370. PubMed ID: 28516342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions.
    Leibowitz MT; Zamora CA; Brzeczko AW; Stark JG
    Am J Ther; 2014; 21(2):99-105. PubMed ID: 22357166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the tamper-resistant properties of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
    Eisenhauer TD; Matchett M; Heasley R; Morton T; Devarakonda K; Giuliani M; Young JL; Barrett T
    Drug Dev Ind Pharm; 2016 Jan; 42(1):157-165. PubMed ID: 26146769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.
    Darwish M; Bond M; Tracewell W; Robertson P; Yang R
    Clin Drug Investig; 2015 Jan; 35(1):13-22. PubMed ID: 25391549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone.
    Webster LR; Bath B; Medve RA; Marmon T; Stoddard GJ
    Pain Med; 2012 Jun; 13(6):790-801. PubMed ID: 22568663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment.
    Malhotra BK; Schoenhard GL; de Kater AW; Friedmann N
    J Opioid Manag; 2015; 11(2):157-69. PubMed ID: 25901481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).
    Meske D; Kopecky EA; Passik S; Shram MJ
    J Opioid Manag; 2018; 14(5):359-372. PubMed ID: 30387859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
    Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects.
    Webster LR; Pantaleon C; Iverson M; Smith MD; Kinzler ER; Aigner S
    Pain Res Manag; 2018; 2018():7276021. PubMed ID: 29849845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
    Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K
    Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).
    Malhotra BK; Matschke K; Wang Q; Bramson C; Salageanu J
    Clin Drug Investig; 2015 Apr; 35(4):267-74. PubMed ID: 25724154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users.
    Webster LR; Smith MD; Lawler J; Lindhardt K; Dayno JM
    Pain Med; 2017 Sep; 18(9):1695-1705. PubMed ID: 27651510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
    Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
    Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Tolerability of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets: Analysis of 11 Clinical Trials.
    Barrett T; Kostenbader K; Nalamachu S; Giuliani M; Young JL
    Pain Pract; 2016 Sep; 16(7):856-68. PubMed ID: 26296448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nasogastric administration of garenoxacin as crushed tablets with and without concomitant enteral feeding in healthy subjects.
    Krishna G; Noveck R; Vargas R; Grasela D; Wang Z
    Drugs R D; 2007; 8(1):43-50. PubMed ID: 17249848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
    Darwish M; Bond M; Ma Y; Tracewell W; Robertson P; Webster LR
    Pain Med; 2017 Jan; 18(1):61-77. PubMed ID: 27330154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of physical manipulation on the oral pharmacokinetic profile of Xtampza
    Gudin J
    J Opioid Manag; 2020; 16(2):127-139. PubMed ID: 32329888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.